NCT01623531View on ClinicalTrials.gov

Prospective Double Blinded Randomized Control Study of the Use of Fibrinogen in High-Risk Cardiac Surgery

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

March 31, 2019

Study Completion Date

June 30, 2019

Conditions

Cardiac Complication During Procedure

Interventions

DRUG

Fibrinogen

Intravenous concentrated fibrinogen will be infused according to a hemostatic algorithm based on ROTEM (FIBTEM)

Trial Locations (1)

B3H3A7

CapitalDHACanada, Halifax

All Listed Sponsors

lead

Nova Scotia Health Authority

OTHER

NCT01623531 - Prospective Double Blinded Randomized Control Study of the Use of Fibrinogen in High-Risk Cardiac Surgery | Biotech Hunter | Biotech Hunter